Up next

Autoplay

Understanding Dayvigo: A Modern Option for Insomnia – With Dr. Farah

0 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

At SolRx, we believe in equipping pharmacists and students with the knowledge to stay current on emerging therapies. In this week’s spotlight, Dr. Farah takes a closer look at Dayvigo (lemborexant) — a newer medication approved in Canada for the treatment of insomnia.

Whether you're a healthcare professional preparing for licensing exams or looking to strengthen your clinical knowledge, this video offers a clear, concise breakdown of how Dayvigo works and what pharmacists need to know.

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. Unlike traditional sedative-hypnotics that act on GABA receptors, Dayvigo works by blocking orexin, a neurotransmitter that promotes wakefulness — offering a different mechanism of action with a lower risk of dependence.

Insomnia is a common complaint in both community and hospital pharmacy settings. With more patients seeking alternatives to benzodiazepines or z-drugs, medications like Dayvigo offer a new approach grounded in sleep physiology. Pharmacists must be prepared to:

Dr. Farah is a lead faculty member at SolRx, known for her ability to simplify complex topics and deliver practice-ready insights for pharmacy professionals. She brings real-world experience and a passion for patient-centered care into every lecture and video.

Show more
0 Comments sort Sort By

Up next

Autoplay